Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sickle Cell Gene Therapy Cost Effectiveness Draws Scrutiny At ASH

Dec 12 2022

• By Alaric DeArment

Stack-100 bills

Related Content

Bluebird Could Find US Tailwind For Zynteglo After ICER Report

Jun 02 2022

Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort

Aug 09 2021

Related Companies

Genetix Biotherapeutics

Novartis AG

Additional Topics

Cost Effectiveness Gene Therapy Pricing Strategies Rare Diseases Commercial BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window